9 Lorenzo F, Nishii K, Monma F, Kuwagata S, Usui E, Shiku H. Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by cerebellar ataxia, telangiectasias, immune defects and a predisposition to malignancy. The birth frequency of A-T is estimated to be about 1 in 100 000-300 000. The A-T heterozygote frequency is estimated to be 0. 1,2 The ATM gene is also known to be mutated secondarily in various hematological malignancies, and is speculated to work as a tumor suppressor gene. 3 ATM protein is one of the members of phosphoinositide 3-kinase-related kinases. Exposure of cells to genotoxic stresses such as anticancer drugs or irradiation induces DNA double-strand breaks. The central player in such DNA damage response is ATM. 4 ATM is present as a dimer or higher-order multimer in unstressed cells with the kinase domain bound to the region surrounding serine (Ser) 1981. Cellular irradiation induces rapid intermolecular autophosphorylation of Ser 1981 and this phosphorylation event results in dimer dissociation and initiation of cellular ATM kinase activity.
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Diagnosis of A-T is based on clinical features combined with laboratory findings. Several cell biological and molecular approaches, such as protein truncation assay, yeast-based protein truncation assay, western blotting, RNA restriction finger printing assay, and others, have been used to reveal ATM mutation prior to straightforward genome sequencing.
2 However, there is no standard method that could be applied in clinical diagnosis, genetic counseling or carrier prediction. Here, we describe a novel method for A-T diagnosis using measurement of phosphorylation status of ATM by flow cytometry.
DNA damage response occurring in cells was monitored by measuring the phosphorylation level of ATM at Ser 1981 using the flow cytometry technique. Phosphorylation of ATM at Ser 1981 is the hallmark of ATM activation and can be detected by the anti-phospho-ATM-specific antibody 10H11.E12 (Cell Signaling, Danvers, MA, USA). Epstein-Barr virus (EBV)-transformed wild-type lymphoblastoid cell line (LCL-WT) was irradiated or treated with hydrogen peroxide (H 2 O 2 ) to induce DNA damage. Dose-dependent phosphorylation of ATM was detected 1 h after irradiation or H 2 O 2 treatment by flow cytometry. An irradiation dose of 0.5 Gy was sufficient to induce phosphorylation of ATM at Ser 1981 and the level of phosphorylation increased in a dose-dependent manner (Figure 1a) . Phosphorylation of ATM was seen in cells treated with 0.1 mM H 2 O 2 , and the level of phosphorylation increased in a dose-dependent manner up to 0.5 mM. 
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Treatment with H 2 O 2 appeared to reach plateau at the doses of 0.5 and 1 mM H 2 O 2 based on the equivalent level of phosphorylation seen by flow cytometry (Figure 1a) . Next, the time kinetics of ATM phosphorylation status was investigated in 10 Gy IR-or 0.5 mM H 2 O 2 -treated cells. ATM phosphorylation was detected 10 min after IR and 15 min after H 2 O 2 treatment, and reached its near-maximum level at 60 min after IR and 30 min after H 2 O 2 treatment (Figure 1b) .
To validate the phosphorylation status demonstrated by flow cytometry in LCL-WT, the same assay was applied to AT52RM, an A-T LCL with null ATM expression by compound heterozygous truncation mutations 7626 C4T/8365 del A, and was compared with that in LCL-WT. Phosphorylation after 10 Gy IR and 0.5 mM H 2 O 2 treatment was detected in LCL-WT but not in AT52RM (Figure 1c) . These results are compatible with the interpretation that the phosphorylation detected by flow cytometry corresponds to ATM phosphorylation. This observation prompted us to investigate whether the flow cytometric monitoring of DNA damage response is applicable for A-T diagnosis in the clinical setting.
Peripheral blood mononuclear cells (PBMNCs) were cultured using media with 700 U/ml interleukin-2 (IL-2) and co-cultured with anti-CD3 antibody, which activates peripheral blood T cells (activated T cell) 6 and provides enough numbers of lymphocytes to analyze ATM activation starting from a small amount of PBMNC. Then, flow cytometric analysis for ATM phosphorylation was employed in wild-type and A-T-derived activated T cells using the same protocol as that for EBVtransformed LCLs. As a result, activated T cells from wild-type control showed substantial increase of phosphorylated ATM after 10 Gy irradiation and 0.5 mM H 2 O 2 treatment. On the other hand, A-T patient-derived activated T cells, which respond to IL-2 and CD3 as much as those of wild-type control (data not shown), showed no ATM phosphorylation (Figure 2a) . Then, it was investigated whether this assay can be applied to PBMNC without stimulation. PBMNC from wild-type or A-T patient was isolated using Percoll gradient and irradiated soon after isolation in RPMI medium with 10% fetal calf serum. At 30 min after irradiation, PBMNC was assessed by flow cytometric analysis for ATM phosphorylation. Wild-type PBMNC showed increased phosphorylation of ATM after irradiation but no phosphorylation was detected in A-T-derived PBMNC (Figure 2b) . These results suggested that flow cytometric analysis for ATM phosphorylation can be applied for the bed-side diagnosis of A-T patients even without precultivation with IL-2 and anti-CD3 antibody.
Next, this assay was tested to see whether the obligate A-T heterozygous carrier is distinguishable from a wild-type individual. Two independent obligate A-T heterozygotederived EBV-LCLs (LCL-Hetero.), 227RM (7517 del 4/wt) and 373 RM (8283 del TC/wt), were enrolled in this study. Both of these LCLs showed increased ATM phosphorylation. However, the intensity of phosphorylation level was rather modest when compared with LCL-WT (Figure 3a) . The phosphorylation level in obligate A-T heterozygotes correlated with the modest level of ATM protein detected by the western blotting method (Figure 3b) .
Diagnosis of A-T is made on the basis of clinical symptoms, including ataxia and telangiectasia and the support of laboratory data. Although the demonstration of lack of ATM protein by western blotting method is a straightforward approach for the screening of A-T patients, ATM protein is not expressed enough to identify wild-type controls in PBMNC, thus making it difficult to distinguish normal, heterozygous and homozygous individuals. Establishment of cell lines or stimulation of PBMNC is required for western blotting analysis. Protein truncation assay is not practical for clinical use because of the complexity of the technique and requirement of several special equipment. Furthermore, these methods failed to identify the missense mutations with normal expression levels of mutant ATM. Sequence-based genetic diagnosis is not easy because of the large size of the ATM gene. The rapid screening methods that precisely predict the presence of ATM mutation will save effort, time and cost for the selection of patients who need whole ATM gene sequencing. Under the light of these previous laboratory experiences, we have eagerly awaited the development of a convenient screening procedure. Here we developed a method to detect the expression levels of phosphorylated ATM protein, which is based on the combinational analyses of ATM protein and its phosphorylation levels. This functional analysis is expected to enable screening of genomic condition of A-T gene before genome sequencing. Flow cytometry is well equipped in most of the clinical laboratories, is relatively easy to manipulate and is easily accessible. Once the procedure is developed, it enables us to share this method between basic and clinical researchers.
The results on EBV-LCLs further suggest that this method will facilitate the diagnosis of heterozygous carriers. Thus, an advantage of our flow cytometric analysis using ATM phosphorylation also exists in the diagnosis of carriers with missense mutations. It was shown that overexpression of dominantnegative form of misssense mutation at the kinase domain interferes with the ATM autophosphorylation after DNA damage. Further investigation is underway to find whether we can identify the individuals with obligatory heterozygous missense mutation by this assay without EBV transformation.
Flow cytometric analysis enables us to screen simultaneously relatively large numbers of patient samples. We have previously reported that activation of DNA damage checkpoints plays an important role in the prevention of leukemic transformation in myelodysplastic syndrome. Phosphorylation of ATM is detected in refractory anemia with excess blast (RAEB)-II phase but not in RA phase. 7 It is often difficult to morphologically classify these two conditions by microscopy. Measurement of ATM phosphorylation using flow cytometry might help to subclassify myelodysplastic syndrome. Furthermore, acquired mutation of ATM gene is frequently identified in hematological malignancies, such as T-prolymphocytic leukemia, mantle cell lymphoma, B-chronic lymphocytic leukemia. Loss of ATM function shows poorer clinical outcome in B-chronic lymphocytic leukemia. 8 The classification of risk groups using ATM activation may add one of the options for selecting the therapy. As with the other clinical applications, measurement of ATM phosphorylation using flow cytometry may be useful for identification of individuals who may show abnormal response against genotoxic stress such as exposure to radiation or chemotherapeutic agents. If these individuals are screened at the bedside, we can avoid the adverse effect of anticancer drugs by reducing the administration doses. Additionally, this screening method will extend the opportunities for risk assessment of cancer development on the basis of population by identifying heterozygous carriers of the ATM gene in individuals with or without cancer.
Expression of cyclin A in childhood acute lymphoblastic leukemia cells reveals undisturbed G1-S phase transition and passage through the S phase Pediatric acute lymphoblastic leukemia (ALL) is characterized by arrested differentiation of the malignant cell clone with retention of proliferative ability. Earlier we had demonstrated that the majority of leukemic cells reside in the G1 phase of the cell cycle, with a minor proportion of cells in the S and G2 phases and only a few cells in the true G0 phase. 1 Although the majority of ALL cells reside in the G1 phase of the cell cycle, attempts to induce differentiation in vivo or in vitro have not been successful.
In view of this arrested differentiation, we became interested in the distribution of ALL cells within the G1 phase relative to the restriction (R) point. The R point determines whether a cell is committed to proliferation or retains the ability to differentiate. 2 Progression through the R point is regulated by the functional inactivation of the retinoblastoma protein (pRb) through a complex stepwise process that includes a sequential phosphorylation by at least two different cyclin-dependent kinase (cdk) complexes, cyclin D/cdk4,6 and cyclin E/cdk2 inducing a loss of nuclear tethering and the activation of E2F transcriptional programs that permit G1-S phase transition. 3 In pediatric ALL cell samples, both cyclin D/cdk4,6 and cyclin E/cdk2 kinase complexes were active; correspondingly,
